<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000513024"><TermName>L-threo-dihydrosphingosine</TermName><TermPronunciation>(... THREE-oh-dy-HY-drose-SFING-goh-seen)</TermPronunciation><TermDefinition><DefinitionText>A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called protein kinase inhibitors. Also called safingol.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000718432" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;L-threo-dihydrosphingosine&quot;" language="en" id="_3"/><MediaLink ref="CDR0000718431" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;L-tri-dihidroesfingosina&quot;" language="es" id="_4"/><SpanishTermName>L-tri-dihidroesfingosina</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de cáncer. Es un tipo de inhibidor de la proteína cinasa. También se llama safingol.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2006-10-14</DateFirstPublished><DateLastModified>2006-10-12</DateLastModified></GlossaryTerm>
